Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
ETCTN 10166
Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer
- NCT03600701 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on ETCTN 10166 (atezolizumab plus cobimetinib) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ETCTN 10166 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Refractory Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8
- Interventions
- Atezolizumab; Biopsy Procedure; Biospecimen Collection; Cobimetinib; Computed Tomography; Magnetic Resonance Imaging
- Arms
- Treatment (atezolizumab, cobimetinib) · Experimental
- Enrollment
- 53
- Primary outcomes
- Number of Participants With a Durable Response
- Sponsor
- National Cancer Institute (NCI)
- Start
- Nov 29, 2018
- Primary completion
- Jul 14, 2025
- Results posted
- Yes
- Registry record
- NCT03600701 · updated Oct 27, 2026